Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists

Journal of the American College of Cardiology

Volumn 73, Issue 12, 2019, Pages 1596-1598

  Vaduganathan, Muthiah ^a   Patel, Ravi B ^a   Singh, Avinainder ^a   McCarthy, Cian P ^a   Qamar, Arman ^a   Januzzi, James L ^a   Scirica, Benjamin M ^a   Butler, Javed ^a   Cannon, Christopher P ^a   Bhatt, Deepak L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADVERSE OUTCOME; CARDIOLOGIST; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL PRACTICE; DRUG INDICATION; DRUG USE; ENDOCRINOLOGY; EVIDENCE BASED PRACTICE; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HUMAN; LETTER; MULTICENTER STUDY (TOPIC); NEEDLE PHOBIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEX RATIO; TERTIARY CARE CENTER; COMPLICATION; DRUG UTILIZATION; FEMALE; FOOD AND DRUG ADMINISTRATION; MALE; MIDDLE AGED; UNITED STATES;

CARDIOLOGISTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85063082625     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.01.029     Document Type: Letter

References (3)

1. Vaduganathan, M., Sathiyakumar, V., Singh, A., et al. Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. J Am Coll Cardiol 72 (2018), 3370–3372.
2. Davies, M.J., D'Alessio, D.A., Fradkin, J., et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the ADA and the EASD. Diabetologia 61 (2018), 2461–2498.
3. Das, S.R., Everett, B.M., Birtcher, K.K., et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the ACC Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 72 (2018), 3200–3223.